Taysha Gene Therapies Market Cap 2020-2024 | TSHA

Taysha Gene Therapies market cap history and chart from 2020 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Taysha Gene Therapies market cap as of January 30, 2025 is $0.31B.
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.307B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $21.004B 7.69
Dr Reddy's Laboratories (RDY) India $11.286B 21.53
BridgeBio Pharma (BBIO) United States $6.891B 0.00
Bausch Health Cos (BHC) Canada $2.701B 1.99
Supernus Pharmaceuticals (SUPN) United States $2.154B 29.32
Amphastar Pharmaceuticals (AMPH) United States $1.751B 10.53
Personalis (PSNL) United States $0.354B 0.00
Assembly Biosciences (ASMB) United States $0.088B 0.00
Sol-Gel Technologies (SLGL) Israel $0.023B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00